[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wrinkles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wrinkles":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,78,103,129,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644275","effect-of-single-facial-acupuncture-on-dermal-structure-and-appearance-satisfaction-100644275",false,"NCT07664280","Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction","Effects of Single-Session Facial Acupuncture on Dermal Structure and Aesthetic Satisfaction: A Randomized Controlled Trial Combining High-Frequency Ultrasound and Patient-Reported Outcomes","FRA","Inclusion Criteria:\n\n* Adults aged 30 to 60 years old. Individuals concerned about facial aging issues.\n* Individuals without severe chronic diseases.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with coagulation disorders.\n* Individuals with a keloid constitution or tendency for abnormal scarring.\n* Individuals with acute or chronic facial hemiplegia\u002Fparalysis of any cause.\n* Individuals who have undergone facial cosmetic surgery or cosmetic injections within the past 6 months.\n* Individuals currently taking anticoagulant medications.\n* Individuals with active skin infections.\n* Individuals with a history of severe allergies.\n* Individuals otherwise deemed unsuitable for facial acupuncture by the investigators.",true,"ALL","30 Years","60 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to investigate the effects of a single session of facial rejuvenation acupuncture on skin structure and personal satisfaction with facial appearance. As facial aging involves complex changes in muscles, skin, and soft tissues, facial acupuncture is considered a potential minimally invasive treatment to help restore balance and promote tissue repair.\n\nResearchers will enroll 60 healthy adults aged 30 to 60 who are concerned about facial aging. Participants will be randomly assigned to either an immediate intervention group or a waitlist control group. The intervention group will receive one session of facial acupuncture at the start of the study. The control group will continue their normal daily skincare routine for 6 weeks, after which they will receive the same single acupuncture treatment.\n\nAll participants will be monitored weekly for 6 weeks. The research team will use non-invasive tools, including high-frequency skin ultrasound, 3D facial scanning, and a digital complexion analysis system, to objectively measure changes in skin thickness, facial volume, and wrinkles. Participants will also complete questionnaires at various time points to share their satisfaction with their appearance, self-confidence, and quality of life.",[29,30,31],"Facial Aging","Wrinkles","Skin Aging",[33,34,35,36,37,38,39,40],"Facial Rejuvenation Acupuncture","Acupuncture Therapy","Dermal Thickness","Skin Rejuvenation","High-Frequency Ultrasound","3D Facial Scanning","Facial Contouring","Patient Satisfaction","RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2026-06-11",{"date":49,"type":23},"2027-08-31",{"name":51,"class":52},"Far Eastern Memorial Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":53},"100631068","post-market-clinical-follow-up-pmcf-study-of-safety-and-performance-of-502-01-angelha-2-100631068","NCT07495865","Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2","A Prospective, Open-label, Non-interventional Post-market Study Evaluating the Performance and Safety of AnGelHA 2 Filler for Correcting Moderate to Severe Wrinkles and Folds and Facial Contour Remodeling in Routine Clinical Use.","Inclusion Criteria:\n\n* Men or women of any race, 18 years of age or older.\n* Able to read, understand and sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women (contraindications as per IFU).\n* Having received prior dermal filler injections in the six months preceding the study.\n* Previously treated with semi-permanent or permanent filler in the intended injection area.\n* Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.\n* Known hypersensitivity to lidocaine and\u002For lidocaine HCl or hyaluronic acid.\n* Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.\n* Undergoing or planning to undergo peeling treatment or laser-\u002Fultrasound-based treatment within 3 weeks before or after injection.\n* Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.\n* Subject, who has a condition or is in Fuse","18 Years",{"count":63,"type":23},87,"OBSERVATIONAL","Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.",[30],[30],"2026-05-26",{"date":70,"type":45},"2026-05-28",{"date":72,"type":45},"2026-02-08",{"date":74,"type":23},"2027-03-12",{"name":76,"class":77},"Glyance","INDUSTRY",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":53},"100624731","prospective-clinical-evaluation-of-the-safety-and-performance-of-the-aesthetic-medical-device-mec-regenerate-injectable-recombinant-collagen-based-product-100624731","NCT07413445","Prospective Clinical Evaluation of the Safety and Performance of the Aesthetic Medical Device MEC REGENERATE® (Injectable Recombinant Collagen-based Product)","Inclusion Criteria:\n\n* Both sexes;\n* Caucasian race;\n* Aged between 35 and 65 years;\n* Non-smokers;\n* Willing and able to return to the study site for post-procedural assessments;\n* Agree to attend all study visits without makeup;\n* Agree not to change their habits regarding diet, physical activity, facial makeup, cosmetics, and facial cleansing products;\n* Agree to avoid intense UV exposure (UV sessions or sunbathing) during the entire study period without adequate sun protection;\n* Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use;\n* Agree to sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnancy (applicable only to non-menopausal female subjects);\n* Breastfeeding (applicable only to non-menopausal female subjects);\n* Smokers;\n* Alcohol abuse and\u002For drug use;\n* Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study;\n* Body mass index (BMI) variation of ±1 during the study period;\n* History of aesthetic skin treatments (biomaterial implants, facelift, botulinum toxin injections, laser therapy, chemical peels) within 6 months prior to the study start;\n* Previous permanent filler treatments;\n* Changes in normal habits related to diet, physical activity, facial cosmetics, facial cleansing, and makeup within one month prior to the study;\n* Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline);\n* Predicted poor compliance with study protocol;\n* Participation in a similar study currently or within the past 9 months;\n* Dermatological clinical conditions that could interfere with aesthetic outcomes;\n* Chronic neurological, immunological, metabolic, cardiovascular, pulmonary, renal, or oncological diseases;\n* Current pharmacological treatment with: Anticoagulants, antiplatelet agents, antihistamines, topical or systemic corticosteroids, narcotics, antidepressants, immunosuppressants (except contraceptive or hormonal treatment started more than 1 year prior); Medications that may affect test results as deemed by the investigator.","35 Years","65 Years",{"count":87,"type":23},20,[26],"Prospective, spontaneous, open-label pre-market clinical trial with a single injection session; monitoring visits at baseline and 60 days post-treatment.\n\nTwo visits will be conducted during the study:\n\n* a baseline visit, during which the first injection will be administered\n* a final visit, 60 days after the baseline visit, for final assessment\n\nThe experimental design involves injection into the deep subdermal layer with the investigational product during the baseline visit, following the study procedure assessments.\n\nTypically, 0.9 ml per side of the face is administered using the retrograde fan technique.\n\nThe study duration is 2 months; safety evaluation will be conducted using non-invasive instrumental assessments such as skin hydration (corneometry) and medical device safety and subjective assessments (see below).",[91,92,30],"Laxity; Skin","Volume Deficiency in the Mid-Face","NOT_YET_RECRUITING","2026-02-12",{"date":96,"type":45},"2026-02-17",{"date":98,"type":23},"2026-03",{"date":100,"type":23},"2026-05",{"name":102,"class":77},"303 Pharma s.r.l.",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100617910","clinical-study-to-assess-safety-effectiveness-and-in-use-tolerability-of-saffron-extract-capsules-for-improving-skin-health-and-reducing-signs-of-aging-on-healthy-adult-male-and-female-subjects-100617910","NCT07324759","Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects.","Effect of Saffron Extract Capsule Supplement on Skin Rejuvenation and Anti-Ageing in Healthy Adult Male and Female Subjects: Randomised, Double-Blind, Two-Group, Prospective, Multi-Centre Exploratory Study","GLOW","Inclusion Criteria:\n\n1. Age: 30 to 55 years (both inclusive) at the time of consent.\n2. Sex: Adult male and female having wrinkles and fine lines at crow feet's area, facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face.\n3. Females of childbearing potential should have a self-reported negative urine pregnancy test at the time of screening visit.\n4. Subjects should not have used any cosmetic, nutraceutical or therapeutic products for skin ageing in last 1 month.\n5. Subjects must be willing to stop using any cosmetics or any medical products for skin ageing for the duration of the study.\n6. Subjects are not allowed to participate in any other study until this study is complete.\n7. Subjects must be willing and able to follow the study directions and to return for all specified visits with the product.\n8. Subjects must agree to record each use of the test products in the subject's diary card on daily basis.\n9. Subjects must agree to record medication use during the study.\n\nExclusion Criteria:\n\n1. Subjects who are on steroids for last six months and using immunosuppressive, anti-inflammatory, or hormone-modulating medications that may interfere with study outcomes.\n2. Subjects who have used any cosmetic, nutraceutical or therapeutic products for skin last one months.\n3. Subjects currently using any oral supplement and topical products containing kojic acid, glycolic acid, niacinamide, alpha arbutin, vitamin C, retinoids, peptides, exfoliating acids, or any other skin-lightening, anti-ageing, or depigmenting agents within the past 4 weeks.\n4. Subjects with a known history of hypersensitivity, allergic reactions, or intolerance (such as drowsiness, stomach discomfort, nausea, or vomiting).\n5. Subjects with other dermatologic diseases whose presence or products could interfere with the assessment of study.\n6. Subjects that are pregnant and\u002For breastfeeding.\n7. The subject has a known allergy or sensitivity to product ingredients.\n8. Subjects if do not agree to limit sun exposure to affected areas such as face during prolonged sun exposure.\n9. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.\n10. The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.\n11. The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data.\n12. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.","55 Years",{"count":113,"type":23},50,[26],"This is a randomized, double-blind, comparative, two-arm, prospective, interventional, multi-centre clinical study to evaluate the safety, efficacy, and in-use tolerability of test products, standardized saffron extract capsules, on skin rejuvenation and age-defying benefits in healthy adult male and female subjects.",[30,117,118,119],"Fine Lines","Hyperpigmentation","Dark Spots","2025-12-24",{"date":122,"type":45},"2026-01-07",{"date":124,"type":23},"2026-01-01",{"date":126,"type":23},"2026-05-30",{"name":128,"class":52},"NovoBliss Research Pvt Ltd",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100598174","per-safpdos-performance-and-safety-of-polydioxanone-suture-100598174","NCT07068061","PER-SAF_PDOS (Performance and Safety of Polydioxanone Suture)","Evaluation of the Performance and Safety of Polydioxanone Suture (PDO) \"Bio Meyisun\" for the Temporary Correction of the Mid-face Area.","PER-SAF_PDOS","Inclusion Criteria:\n\n* Patients over 18 years old with full legal capacity, male and female;\n* Patients with ability to understand the proposed aesthetic correction and to understand and sign informed consent;\n* Patients who are willing and able to comply with scheduled visits, aesthetic correction procedure and other trial procedures.\n\nExclusion Criteria:\n\n* Pregnant or breast--feeding women;\n* Patients currently participating in any other clinical investigation;\n* Patients who have received a vaccine within 14 days prior to the baseline or plan to have vaccine within 14 days after the injection;\n* Patients with a medical history of systemic diseases, including severe kidney, liver, heart and neurological disorders.",{"count":113,"type":23},[26],"This clinical investigation aims to confirm the safety and efficacy of the ID in facial soft tissue reconstruction, specifically for non-incision surgery to tighten and lift the facial skin for a rejuvenated facial appearance.",[30,141,142],"Anti Aging","Face-lift","2025-07-14",{"date":145,"type":45},"2025-07-16",{"date":147,"type":23},"2025-09-01",{"date":149,"type":23},"2026-07-01",{"name":151,"class":77},"21 Century Medical Co., Ltd.",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":17,"sex":18,"minAge":158,"maxAge":20,"enrollmentInfo":159,"targetDuration":161,"studyType":64,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100583074","quantified-evaluation-of-whole-face-8-points-supra-periosteum-high-molecular-weight-hyaluronic-acid-injection-in-asian-100583074","NCT06871592","Quantified Evaluation of Whole Face 8-points Supra-periosteum High Molecular Weight Hyaluronic Acid Injection in Asian","Inclusion Criteria:\n\n1. Men and women aged between 20 and 60.\n2. Subjects who are capable of understanding and comply with the study procedures, instructions, and visit schedule.\n3. Subjects who voluntarily decide to participate in the entire course of the trial and provide written consent in the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Subjects with a history of anaphylaxis, allergy hyaluronic acid products, or any component of devices.\n2. Subjects with autoimmune diseases\u002F received immune system and Subjects with diabetes mellitus.\n3. Subjects with a history of a hypertrophic scar.\n4. Pregnant or breastfeeding women.\n5. Subjects with epilepsy or underlying porphyria.\n6. When there is inactive disease (such as inflammation, infection or tumours) in or near the intended treatment site.\n7. Treatment procedure (e.g., bioresorbable fillers, laser\u002Flight therapies, botulinum toxin A injections, face lift, facial peels, excisional facial surgery, dermal photorejuvenation clinically significant oral or maxillofacial surgery, etc.) that may interfere with the treatment area or evaluation within 6 months prior to screening as determined by the Principal Investigator.\n8. The subject who received soft tissue augmentation as following at the investigational medical device injection site within 6 months prior to screening as determined by the Principal Investigator.\n9. The subject who received soft tissue augmentation near the injection site with any of the following at any time.\n10. Subjects with a scar or skin lesion at the investigational medical device injection site that may interfere with the judgment of the treatment effect.\n11. Subjects who participated in another clinical trial within 60 days prior to screening or plan to participate in another investigation during the course of this study.\n12. Subjects who plan to receive other wrinkle improvement treatment in the face during this trial.\n13. Subjects who are otherwise determined by the investigator as ineligible for this study.","20 Years",{"count":160,"type":23},25,"6 Months","Facial aging is a complex process characterized by skin atrophy, subcutaneous fat loss, and alterations in bone structure. The loss of volume, primarily due to bone resorption and loss of adjacent fat volume from different facial regions, leads to soft tissue flattening. Hyaluronic acid (HA) is a widely used biomaterial in clinical practice, known for its excellent tissue compatibility, low risk, and safety. Previous research and clinical practice have demonstrated that HA for facial lifting can help restore facial fullness, elasticity, and promote a more youthful appearance. Dermatologist previously utilized the supra-periosteum lift technique in high molecular weight hyaluronic acid injection. It was found that the material properties of high molecular weight hyaluronic acid not only made it suitable for filling but also provided lifting support, resulting in improvements in cheek fullness and facial aging. However, there has been no detailed quantitative study on the efficacy of high molecular weight hyaluronic acid for facial lifting.\n\nTo further investigate this effect, the investigators plan to conduct a prospective, open-label clinical trial. The investigators will recruit 25 adult and use an 8-point supra-periosteum facial lifting technique to inject high molecular weight hyaluronic acid. Assessments will be conducted preoperatively, postoperatively, and 4 weeks, 12 weeks and 24 weeks postoperatively to analyze the treatment efficacy. The eight injection points will be located at the brow peak, brow tail, pterion, lateral canthus, zygomatic ligament, mid-cheek, nasolabial fold, and mentalis. The investigators will use evaluation forms with four angles and six lengths, as well as the Global Aesthetic Improvement Scale, to quantify the degree of improvement in facial aging. Additionally, The investigators will use a satisfaction survey to understand subjects' perceptions of postoperative lifting effects and overall improvement satisfaction. The investigators hypothesized this study to improve facial aging in Asian patients and provide long-lasting effects.",[30],"2025-03-11",{"date":166,"type":45},"2025-03-13",{"date":168,"type":23},"2025-03-20",{"date":170,"type":23},"2026-02-27",{"name":172,"class":52},"Chang Chang Cheng"]